Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2023 · 10-Q
Revenue$880.00K$880.00K+118.4% vs Q1 2022 Net Income-$10.65M-$10.65MN/M vs Q1 2022 EPS Diluted-$0.01-$0.01N/M vs Q1 2022 Operating Income-$12,964,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1473.2%+1575.5 pt vs Q1 2022
Net margin-1210.5%+2316.6 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end